Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The expected outcome of the call is to improve the efficacy of current detection, diagnosis, prognosis and treatment of cancers, through the development of novel approaches based on a better understanding of cancer epigenetics.
Característiques principals
The specific objectives of this funding opportunity are to stimulate new partnerships between researchers and clinicians and support original, high-quality projects, with significant clinical impact.
In the context of translational research, this topic will comprise two general aims, each with several aims, which concur to the possible clinical applications. Proposals should cover one or several of the specific aims listed below and should be built from a sound hypothesis. Particular attention should be given to gender balance inclusion in order to intercept sex/gender differences and to consider the role of these differences in the addressed questions.
  • Aim 1) The role of epigenetics in cancer initiation and progression.
  • Aim 2) Validation of new epigenetics-based therapeutic strategies to limit cancer progression, prevent relapse/recurrence or increase the efficiency or reduce toxicity of existing anti-cancer therapies.
    • Lloc de presentació
    IMIM and PSMAR staff who need more information should contact::
    Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    https://transcan.eu/funding/calls/joint-call-jtc-2023-.kl
    Informació addicional
    Aplicatiu web: https://ptoutline.eu/app/transcan2023
    Requisits
    Consortia composition (see the Call Text for complete information):
  • Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners, eligible for funding, coming from different countries whose funders participate in the call.
  • In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, therefore the maximum number of partners can be increased up to seven (7) if they include one partner from the following participating countries: Hungary, Latvia, Slovakia and Turkey.
  • The partners must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from the same country (in such cases the minimum number of groups must be 4, coming from 3 different countries).
    For Spanish applicants: please check the eligibility requirements of the institution and the principal investigator/team members, in pages 44-52 of the Guidelines.

    		•
    Dotació
    200.000€ to 550.000€ depending on the role (coordinator or partner) and the number of Spanish beneficiaries
    Durada
    24 to 36 months
    AVÍS IMPORTANT
    En cas de voler presentar-vos a la convocatòria, per favor no contacteu directament amb ISCIII/FCAECC, dirigiu-vos al Servei de Recerca (Carol Barnwell / Marta López)

    Arxius

    Arxiu
    TRANSCAN-3_Guidelines_for_applicants_JTC2023_final.pdf
    TRANSCAN-3_Call_text_ JTC2023_final.pdf